Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Induction of Remission in Ulcerative Colitis
NCT00385736Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Nov 2006
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in ulcerative colitis (UC) (3 arms), sponsored by Abbott Laboratories. Primary endpoint: Proportion of Participants With Clinical Remission Per Mayo Score at 8 weeks. Started Nov 2006; status: completed.
02
Drugs
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00385736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385736.